(S)-Veliflapon

Cat. No.: HY-14165A

CAS No.: 128253-32-7

Molecular Formula: $C_{23}H_{23}NO_3$

Molecular Weight: 361.43

Target: Leukotriene Receptor; FLAP

Pathway: GPCR/G Protein; Immunology/Inflammation

Storage:

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (276.68 mM; Need ultrasonic)

Preparing Stock Solutions	Mass / Solvent / Concentration	1 mg	5 mg	10 mg
	1 mM	2.7668 mL	13.8339 mL	27.6679 mL
	5 mM	0.5534 mL	2.7668 mL	5.5336 mL
	10 mM	0.2767 mL	1.3834 mL	2.7668 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

(S)-Veliflapon ((S)-BAY X 1005) is an orally active inhibitor of leukotriene biosynthesis and 5-lipoxygenase activating protein (FLAP). (S)-Veliflapon inhibits the formation of leukotriene B4 (LTB4) in rat, mouse and human leukocytes with IC_{50} values of 0.026 μM, 0.039 μM and 0.22 μM respectively. (S)-Veliflapon showes enantioselectivity in human whole blood[1][2][3].

In Vitro

(S)-Viliflapon decreases leukotriene B4 (LTB4) synthesis in human whole blood with dose-dependent manner[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Fruchtmann R, et al. In vitro pharmacology of BAY X1005, a new inhibitor of leukotriene synthesis. Agents Actions. 1993 Mar;38(3-4):188-95.

[2]. Hermann, David J., et al. Dosing schedules of leukotriene synthesis inhibitors for human therapy. World Intellectual Property Organization. WO2009002746.

[3]. Helgadottir, et al. Polymorphisms in the susceptibility genes for myocardial infarction, stroke, and peripheral artery occlusive disease and their use in risk assessment

and prophylaxis therapy. United States. US20070280917.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA